Bayer is a primary, foundational pillar of the global chemical and pharmaceutical industry. Founded in 1863 in Barmen, Germany, by Friedrich Bayer (a dye salesman) and Johann Friedrich Weskott (a master dyer), the company originally manufactured synthetic dyestuffs. However, the company's core, world-altering breakthrough occurred in 1897 when a young Bayer chemist named Felix Hoffmann synthesized acetylsalicylic acid in a stable, pure form. Bayer trademarked and marketed this substantial invention globally as "Aspirin," essentially creating the modern, mass-market pharmaceutical industry and establishing Bayer as a trusted, major global household name.
The Diversified Life Sciences Conglomerate
Throughout the 20th century, Bayer operated as a significant, complex, sprawling German chemical and pharmaceutical conglomerate. By the early 21st century, recognizing that substantial, diversified conglomerates were inefficient, Bayer executed a vast strategic focus entirely on "Life Sciences." They spun off their large, legacy materials science and plastics division (which became Covestro) to focus their extensive capital entirely on two distinct areas that addressed large global megatrends: Pharmaceuticals (treating an aging global population) and Crop Science (providing the advanced seeds and chemicals required to feed a rapidly expanding global population).
The Monsanto Megadeal (The Ultimate Poison Pill)
The defining, catastrophic strategic disaster of modern Bayer occurred in 2018. Under the aggressive leadership of CEO Werner Baumann, Bayer executed a, $63 billion hostile takeover of Monsanto, the, controversial American titan of agricultural seeds and herbicides. The strategic logic was to create a true, dominant global monopoly in agriculture. However it is widely considered the worst corporate acquisition in modern history. The significant deal was criticized by investors and despised by environmental activists globally.
The Roundup Litigation Nightmare
The true, devastating cost of the Monsanto acquisition was not the $63 billion purchase price; it was the, hidden legal liability. Monsanto manufactured Roundup, the most widely used chemical weedkiller on earth (glyphosate). Almost immediately after the acquisition closed, American juries began returning, multi-million-dollar verdicts against Bayer, ruling that Roundup caused a specific type of cancer (Non-Hodgkin's Lymphoma) and that Monsanto had actively covered up the risks. Bayer was suddenly hit with a substantial tsunami of over 100,000 aggressive lawsuits. The legal settlements (exceeding $10 billion) crippled Bayer's balance sheet and destroyed amounts of shareholder value.
The Patent Cliff and the Restructuring Pressure
Today Bayer is a large, damaged corporation fighting a desperate battle for survival. The financial drain of the Roundup litigation has severely starved the profitable Pharmaceutical division of critical R&D funding. This is for Wall Street, because Bayer faces a large, imminent "patent cliff" on its two biggest blockbuster drugs (Xarelto and Eylea). The new CEO, Bill Anderson, is executing an aggressive, formidable corporate restructuring, firing thousands of managers to eliminate the toxic, extensive German bureaucracy. Crucially Anderson is facing prominent, relentless pressure from aggressive activist investors to dismantle the 160-year-old company, demanding that the profitable pharmaceutical business be officially spun off to finally escape the prominent, toxic shadow of Monsanto.
